High performance enrichment-based genome sequencing to support the investigation of hepatitis A virus outbreaks

Authors

Sara E. Zufan[1,2], Karolina Mercoulia[1,3], Jason Kwong[4,5], Louise M. Judd[1,6], Benjamin P. Howden[1,2,3], Torsten Seemann[1,2,3], Timothy P. Stinear[1,2]

Affiliation(s)

[1]Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia

[2]The Centre for Pathogen Genomics, The University of Melbourne, Melbourne, VIC, Australia

[3]Microbiological Diagnostic Unit Public Health Laboratory, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia

[4]Department of Infectious Diseases, Austin Health, Heidelberg, VIC, Australia

[5]Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia

[6]Doherty Applied Microbial Genomics, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia

Corresponding author

Sara E. Zufan, s.zufan@unimelb.edu.au

Keywords

Public health genomics, culture-independent diagnostics, whole genome sequencing, food-borne surveillance, molecular epidemiology

Abstract

Hepatitis A virus (HAV) infections are an increasing public health concern in low-endemicity regions due to outbreaks from foodborne infections and sustained transmission among vulnerable groups, including persons experiencing homelessness, those who inject drugs, and men who have sex with men (MSM), which is further compounded by aging, unvaccinated populations. DNA sequence characterisation of HAV for source tracking is performed by comparing small subgenomic regions of the virus. While this approach has been successful when robust epidemiological data are available, poor genetic resolution can lead to conflation of outbreaks with sporadic cases. HAV outbreak investigations would greatly benefit from the additional phylogenetic resolution obtained by whole virus genome sequence comparisons. However, HAV genomic approaches can be difficult because of challenges in isolating the virus, low sensitivity of direct metagenomic sequencing in complex sample matrices like various foods such as fruits, vegetables and molluscs, and difficulty designing highly multiplexed PCR primers across diverse HAV genotypes. Here, we introduce a proof-of-concept pan-HAV oligonucleotide hybrid capture enrichment assay from serum and frozen berry specimens that yields complete and near-complete HAV genomes from as few as four input HAV genome copies. We used this method to recover HAV genomes from human serum specimens with high $C\tau$ values (34·7—42·7), with high assay performance for all six human HAV sub-genotypes, both contemporary and historical. Our approach provides a highly sensitive and streamlined workflow for HAV WGS from diverse sample types, that can be the basis for harmonised and high-resolution molecular epidemiology during HAV outbreak surveillance.

Importance

This proof-of-concept study introduces a hybrid capture oligo panel for whole genome sequencing (WGS) of all six human pathogenic hepatitis A virus (HAV) sub-genotypes, exhibiting a higher sensitivity than some conventional genotyping assays. The ability of hybrid capture to enrich multiple targets allows for a single, streamlined workflow, thus facilitating the potential harmonization of molecular surveillance of HAV with other enteric viruses. Even challenging sample matrices can be

53   accommodated, making it suitable for broad implementation in clinical and public health laboratories.

54   This innovative approach has significant implications for enhancing multijurisdictional outbreak

55   investigations, as well as our understanding of the global diversity and transmission dynamics of

56   HAV.

Introduction

Hepatitis A is a vaccine-preventable disease caused by hepatitis A virus (HAV), a nonenveloped virus, with a small (7.5kb) positive-sense RNA genome in the family *Picornaviridae*. HAV is transmitted faecal-orally, by consuming contaminated food or drink, as well as person-to-person between close contacts.[1] It is the leading cause of acute viral hepatitis, symptoms can be prolonged but rarely result in fulminant hepatitis. Endemicity can be classified as high, intermediate, low, or very low and is generally associated with socioeconomic indicators such as hygienic and sanitary conditions.[2] Incidence of HAV infections declined in many low-endemicity countries after the implementation of routine childhood immunization by the early 2000s.[3,4] As a result, immunity in adult populations has declined significantly, thereby increasing the number of susceptible individuals who are more likely to experience and report symptoms of hepatitis.[5] Epidemiology in these regions then shifted from cyclical community wide outbreaks associated with childcare facilities or households with children, to sporadic outbreaks stemming from travellers or consumption of contaminated food from high- and intermediate-endemicity regions.[2,6–9] Another epidemiological shift began in 2016 when several North American and European countries observed a sharp increase in cases driven by person-to-person transmission, particularly in vulnerable populations including persons reporting injection drug use, experiencing homelessness, and men who have sex with men (MSM).[10–19] The combination of infection in older adults and persons with one or more comorbidities has resulted in an uptick in hospitalisations and death related to HAV infection.[5,13,20,21]

Human pathogenic HAV can be characterised into three genotypes (I, II, II), each with two subgenotypes (A, B). Distribution of subgenotypes varies geographically, although IA accounts for more than half of all reported cases.[22] Combined with epidemiological data, subgenotyping has been shown to improve outbreak characterisation and response by differentiating between sporadic and outbreak cases, determining the source of infection, and tracking chains of transmission.[17,18] Several genome regions are used for HAV genotyping. The most common regions in HAV query databases are found in or around a 168 nt fragment of the VP1/2A junction.[22–24] However, the accuracy of phylogenetic relationships inferred using these small regions has been put into question by several

studies that found significant variations in genetic relatedness when comparing different subgenomic

regions.[25–27]

WGS comparisons have become increasingly employed for viral surveillance and outbreak detection

as variation across the entire virus genome can increase the spatial and temporal phylogenetic

resolution of molecular epidemiology.[28] Indeed, Vaughn et al. found that subgenotyping could yield

misleading transmission interpretations when applied to cases with unknown epidemiological

associations, demonstrating that WGS was able to differentiate between sporadic and outbreak cases

with identical VP1/2A sequences.[27] This additional resolution could be particularly useful for guiding

response to growing person-to-person transmission. For example, a recent analysis of a large outbreak

in New York (USA) found a cluster of identical VP1/2A sequences from neighbouring jurisdictions.

WGS revealed 3-41 single nucleotide variants (SNVs) between cases, where the case with the greatest

nucleotide difference had travelled to Florida, suggesting the infection was acquired outside of the

local outbreak.[29]

Despite the potential benefits, WGS of HAV in a public health context has been challenging for

several reasons. First, HAV grows poorly in cell culture, making isolation infeasible for routine

culture-based WGS. Second, despite moderate genetic diversity compared to other RNA viruses,

enough heterogeneity across the genome exists to make it difficult to design primers for multiplex

amplicon sequencing.[30,31] Recently, two primer schemes for HAV WGS have been designed targeting

IA and/or IB, where an effort to incorporate additional subgenotypes reduced primer efficiency.[29,32]

Both studies had difficulty reliably recovering whole genomes from serum samples above 30 Cτ.

Alternatively, hybridisation capture is a highly flexible option for culture-agnostic WGS. Unlike

PCR-based amplification, hybrid capture reactions can contain hundreds of thousands of

oligonucleotide baits (probes) without interactions and are unaffected by amplification inhibitors in

complex sample matrices. Furthermore, conservative tiling probe design can improve the ability to

capture novel sequences as well as increase sensitivity in degraded samples. These characteristics

make it an ideal solution for routine WGS in public health laboratories for pathogens like HAV that

are genetically diverse and present in a variety of complex sample matrices. The flexibility of probe

design can also be leveraged to incorporate additional enteric pathogens, which can streamline library

preparation and increase the sequence throughput of routine diagnostic or surveillance workflows.

Here, we present a hybridisation capture panel for undertaking WGS designed to be highly sensitive

across all HAV human subgenotypes. We demonstrate the sensitivity of the capture panel to recover

WGS from food (berry) and human serum samples spiked with serially diluted HAV RNA ranging

from 27·9 copies/µL to below the limit of detection (LOD) (<0·2 copies/µL), corresponding to cycle

threshold (Cτ) values 33·8 to >42·0. We also use the panel to recover complete and near complete

(93·3%) genomes from clinical serum samples of infected patients, with and without subgenotyping

data available. Finally, we use *in silico* prediction to extrapolate the efficiency of the panel to capture

subgenotypes not evaluated in this study.

Materials and Methods

Pan-HAV probe design

123 Complete genomes of human pathogenic HAV were downloaded from GenBank on 25 Jan 2021 (N =

124 164). Genomes were manually selected for temporal and geographic representation of each

125 subgenotype (N = 44). Probes were designed by IDT as previously described using a 120-mer 1X

126 tiling approach.[33]

Optimisation experiment

Sample preparation

128
129

Food samples were prepared with frozen mixed berries according to International Organization for

Standardization report ISO 15216-1:2017 with two modifications.[34] First, RNA extraction was

performed on a QIASymphony with a custom protocol using the DSP Virus/Pathogen Kit with an

input volume of 800µL and elution volume of 60µL. The second modification was the use of an

Applied Biosystems 7500 Fast DX system for detection and quantification. "Low", "mid", and "high"

virus-spiked berry specimen were prepared based on ISO 15216-2:-2019 validation studies.[35] For

serum samples, ultraconcentrated spike-in material was prepared by resuspending one LENTICULE

disc (RM000HAV) in 222μL PBS, followed by 10^{-1} serial dilutions in human sera. RNA extractions

were again performed using a QiaSymphony using the DSP Virus/Pathogen Kit with an input volume

of 200μL and elution volume of 60 μL. Quantification of target copies per microliter of sample RNA

was performed as described in ISO 15216-1:2017. HAV LENTICULE discs were used for both the

quantification standards and as the spike-in material.

The volume of RNA extracts was equally divided to create four experimental variables: pre-

enrichment, pre-enrichment with concentration, post-enrichment, and post-enrichment with

concentration. A subset of samples were concentrated two-fold using the Zymo Clean and

Concentrate -5 kit including on-column DNAse treatment with a final elution volume of 10μL.

Constructing sequencing libraries
147

Sequencing libraries were prepared by Illumina RNA Prep with Enrichment with 8.5μL RNA input,

according to the manufacturer's protocol. Total RNA for all samples was below the recommended 10

ng. Briefly, RNA is synthesized to cDNA, followed by tagmentation library preparation. The indexed

library is then hybridized with the custom probe panel, captured, and, finally, PCR amplified. Pre-

enrichment controls were removed from the workflow after purification of the indexed library.

Enriched sample libraries were normalised to 200ng and pooled for three-plex hybridisation overnight

(16 hours) using the previously described pan-HAV probes (100uM). Final sequencing libraries were

normalised to 20nM prior to pooling for sequencing on an Illumina NextSeq2000 using a P1 2 x 150

bp reagent kit.

Analysis of pre- and post-enrichment libraries
158

Reads were adapter trimmed using cutadapt (v.2.6) with parameters -a CTGTCTCTTATACACATCT

-A CTGTCTCTTATACACATCT for paired-end trimming of universal dual indices.[36] Taxonomic

classification of trimmed reads was performed with Kraken 2 (v.2.1.2) using the viral RefSeq

database indexed on 05 May 2021 (available from https://benlangmead.github.io/aws-indexes/k2).[37]

Trimmed reads were mapped to the spike-in material reference sequence (GenBank accession

M59809.1) using minimap2 (v.2.18-r1015) with parameters -ax sr.[38,39] PCR duplicates were removed

from the mapped reads using samtools *markdup* (v.1.17).[40] Mapping and quality metrics were

obtained from samtools *samstats* and qualimap *bamqc* (v.2.2.2a), and collated with multiQC

(v.1.14).[41,42]

Application to clinical specimen

Patient samples

Archived serum samples, collected in Victoria, AUS between February and May 2023, from two

infected patients were referred to the Microbiological Diagnostic Unit Public Health Laboratory for

HAV WGS. A single patient had two samples taken one month apart (AUSMDU00085964,

AUSMDU00085966). AUSMDU00085964 was referred with subgenotype documented as IIIA, but

no subgenotype data was provided for the second referral (AUSMDU00085965). Ethical approval

was granted from the University of Melbourne Human Research Ethics Committee (HREC no. 2021-

22158-20072-2).

Sample preparation and sequencing

RNA extraction and quantification were performed as described earlier for serum samples. Prior to

library preparation, RNA extracts were vacuum concentrated 3·7-fold for 26 minutes at ambient

temperature. Library preparation was performed as described earlier in duplicate with ~7.5μL input

RNA. Total RNA was below the limit of quantification by Qubit HS RNA assay. Libraries were

normalised to 4nM prior to pooling for sequencing on an Illumina iSeq 100 using an i1 2 x 150bp PE

reagent v2 kit.

Analysis of clinical sequences

Reads were quality controlled as described earlier. To determine the subgenotype of

AUSMDU00085965, deduplicated reads were filtered to discard those that were taxonomically

unclassified. Filtered reads were *de novo* assembled using SPAdes (v.3.15.5) with the rnaviral

parameter enabled.[43] The longest contig was queried against a local nucleotide (nt) database of HAV

sequences from GenBank and HAVNet using BLAST (v.2.14.0) with an e-value threshold of 10^{-4}.[44,45]

The highest scoring matches belonged to subgenotype IIIA. Deduplicated reads for all samples were

then mapped to the most recently available complete IIIA genome (MN062167.1) collected in 2019

from California, USA.[17] Variants were called using samtools *mpileup* and iVar *consensus* (v.1.0) with

parameters -m 10 -q 30 -t 0.9.[46] Mapping and quality statistics were obtained as before. Duplicate

sample reads were concatenated to create high quality consensus genomes and were deposited to

GenBank.

Two sets of context sequences were selected for phylogenetic analysis, which were obtained by

querying the individual whole genomes (*WG-query*) and the extracted VP1/2A region (*VP1/2A-query*)

sequences against the local nt HAV database to retrieve the 50 highest scoring matches for each

patient. These highest matching sequences to each patient were combined into a single WG-query or

VP1/2A-query multifasta file and duplicate sequences were removed. Three alignments were created

using MAFFT (v.7.520): WGS consensus sequences with WG-query sequences, VP1/2A consensus

sequences with VP1/2A-query sequences, and WGS consensus sequences with VP1/2A-query

sequences.[47] Maximum-likelihood phylogenetic tree construction was performed with IQtree

(v.2.2.2.3) using the best-fit model and 1000 bootstrap replicates.[48]

In silico probe efficiency assessment

Complete and near complete (>95%; >7051nts) genomes of hepatitis A virus from human hosts were

downloaded from GenBank on 24 April 2023 (N=239). Sequences used to create the probe panel were

removed, with the exception of the single available IIB genome (AY644670.1), the remaining

sequences were randomly subsampled to account for oversampling from outbreak studies by selecting

no more than three sequences per country and year for each subgenotype using augur *filter grep*

(v.21.1.0) (N=86) plus the spike-in control sequence.[49] ProbeTools (v.0.1.9) modules *capture* and

stats were used to align the pan-HAV probe sequences against the selected target sequences to assess

probe coverage and depth.[50] ProbeTools *getlowcov* was used to find low coverage regions, defined as

120-kmers with zero probe coverage at more than 40 consecutive sites. A Mann-Whitney U test was

performed to evaluate whether the low probe coverage regions identified in the control sequence had

significantly lower read depth compared to the rest of the genome in enriched samples using scipy

(v.1.18.1).[51]

Data Availability

Complete genome sequences from AUSMDU00085964 and AUSMDU00085965 were deposited in GenBank (Accessions: OR261026, OR261027). Additional data and supplemental materials are available from https://doi.org/10.26188/23648025.

Results

Pan-HAV probe design

A total of 425, 120-mer biotinylated oligonucleotide probes were selected to achieve a minimum 1X tiling across the representative target genomes (Supplemental Tables 1-2).

Optimisation experiment

Frozen berries and serum spiked with "high", "mid", and "low" viral genome titres of HAV RNA corresponded to Cτs 35·1, 40·1, and Undetermined (<LOD) for berries, and 33·6, 36·6, and 41·0 for serum, respectively (Table 1). In berries, between 0—5 unique on-target reads were detected in the unenriched samples, yielding no genome coverage with a minimum read depth of 10x. In serum, between 69—346 unique on-target reads were detected in unenriched samples, yielding genome coverage ranging from 0—1.9% with a minimum read depth of 10.

An increase in read depth and genome coverage was observed in all enriched samples. After enrichment of berry libraries, mean-fold enrichment increased the read depth by 315·2x in high-titre samples with concentration treatment and 21·4x without; by 3·5x in mid-titre samples with concentration and 7·3x without; and by 3·6x in low-titre samples with concentration and 1·3x without (Figure 1A). Up to 74%, 2·3%, and <0·1% of the genome was recovered from high-, mid-, and low titres at a minimum read depth of 10, respectively. Target reads were present at ≥ 1 depth up to 99·5%, 81·8%, and 11·7% of the genome positions in high-, mid-, and low-titre berry samples, respectively (Figure 1B). After enrichment of serum libraries, mean-fold enrichment increased the read depth by 368·9x in high-titre samples with concentration and 662·3x without; by 109·5x in mid-titre samples with concentration and 23·0x without; and by 3·1x in low-titre-samples with

245 concentration and 3·0x without (Figure 1A). Up to 100%, 80·8%, and 10·3% of the genome was

246 recovered from high-, mid-, and low titres using a minimum read depth of 10, respectively. Target

247 reads were present at ≥ 1 depth up to 100%, 100%, and 91·4% of positions in high-, mid-, and low-

248 titre serum samples, respectively (Figure 1B).

Patient samples

One patient sampled twice over a one-month period had a Cτ value of 35·8 for the first

(AUSMDU00085964) and 42·7 for the second (AUSMDU00085966). AUSMDU00085965 had a Cτ

value of 34·7 (Table 1). Genotyping was available for AUSMDU00085964, thus presumed for

AUSMDU00085966, reported as IIIA. The genotype for AUSMDU00085965 was determined to be

IIIA using the longest *de novo* assembled contig (3482nt) queried against the local HAV database.

Enriched libraries of AUSMDU00085964, AUSMDU00085966, and AUSMDU00085965 were

comprised of up to 12·9%, 17·2%, and 0·9% HAV classified reads (Figure 2A), yielding a mean

depth up to 2455·3X, 24·3X, and 3446·4X unique target reads (Table 1), respectively. The complete

genome (100%) was recovered for AUSMDU00085964 and both AUSMDU00085965 replicates,

while 89·5% and 93·3% were recovered for AUSMDU00085966 replicates using a minimum read

depth of 10. Target reads were present at ≥ 99·9% of genome positions in all samples (Figure 2B).

Comparing the nucleotide differences in the WG and VP1/2A region (503 nt) between the complete

sequences of both patients, there are 80 (0·011 substitutions/site) and 6 SNVs (0·012

substitutions/site), respectively. All 51 of the context sequences obtained by querying the WG

sequences were >7kb, while 71·2% of the 52 context sequences obtained by querying the VP1/2A

sequences were <1kb. Phylogenetic analysis of the WG sequences with WG-query context samples

places the patient samples in the most recent clade descending from a clade of strains collected from

India in the early 2000s (Figure 3A). Patient samples cluster together in the tree of VP1/2A sequences

with VP1/2A-query context samples amongst contemporary sequences, primarily collected in

European countries (Figure3B). In the tree comparing WG sequences with VP1/2A-query context

samples, patient samples are similarly found in a contemporary European clade but are distributed

further apart (Figure 3C).

 In silico **prediction**

A table of accession numbers and metadata for sequence data used for *in silico* prediction are

available in Supplemental Table 3. On average, 98·6% of the queried target positions were covered by

one or more probes (median 99·2, IQR 98·8—100). Subgenotypes I—IIIA and IIB are covered by one

or more probes at >99·1% positions, while IB and IIIB have 97·7 and 92·8% coverage, respectively

(Figure 4). Amongst strains with more than one target sequence, an average of 1·1 low probe

coverage regions were identified. The single IIB and IIIB strains had zero and 5 low probe coverage

regions, respectively. Three low probe coverage sites were predicted in the control sequence between

positions 1690—1809, 2633—2752, and 6730—6849, none of which had significantly lower read

depth compared to the rest of the genome.

282 Discussion

283 We present a hybrid capture oligo panel for WGS of all six human pathogenic HAV subgenotypes

284 from serum and food samples, demonstrating a highly sensitive and generalized HAV WGS workflow

285 for outbreak surveillance. This approach is a more cost-effective alternative to HAV WGS by

286 metagenomic sequencing, can be used with degraded or challenging sample matrices, and can be

287 employed without *a priori* genotyping.

288 Optimisation experiment

Enrichment of the complete HAV genome from berry specimen was observed as low as 83 input

copies, and near complete (78·3%) from 4 input copies, providing the most cost-effect approach of its

kind to date. Previously, deep metagenomic sequencing had recovered a near complete HAV from

frozen raspberries, generating 5M reads and yielding a mean read depth of 60.[52] Lower HAV read

depth observed in berry specimen compared to serum may be attributed to lower genome input copies

and an over fragmented library. To address the former, future optimisation should increase the input

volume into the concentration workflow to both remove residual inhibitors and increase input viral

RNA. Regarding the latter, the vigorous purification process necessary for removing inhibitors from

food samples resulted in nearly all sequencing libraries having average read lengths <120

(Supplemental Figure 1). Previous work has reported reduced hybridisation efficiency when the mean

insert size of the library was shorter than probe length.[53] Another possibility is residual inhibitors

present in the berry RNA extracts could negatively affect cDNA synthesis and tagmentation prior to

hybridisation, which could explain why mean-fold enrichment of cleaned and concentrated berry

samples was significantly greater than the untreated berry samples at high-titre. Whereas the inverse

was observed in lower-titres, and serum, suggesting sample loss in the spin-column outweighs the

benefits of purification (Figure 1A). It is recommended that future optimisation includes concentration

from higher input volumes to increase viral RNA input, and further determination of titres suitable for

column-based purification for food or other complex matrices. Additional troubleshooting is needed

to minimize over fragmentation during library tagmentation.

In serum samples, the complete genome was recovered from as few as 65 input copies, and near-

complete (91·4%) from 4 input copies. These results are similarly sensitive compared to amplicon-

based sequencing for HAV WGS from serum but offers a simplified solution for routine sequencing

in public health laboratories. For instance, the IA scheme presented by Lee et al. yielded a maximum

of 94·7% genome coverage in specimen with Cτs ranging from 27·6 to 33·3. Cleary et al. designed a

scheme for IA-B where nearly half of the samples with Cτ values between 16-40 yielded >=95·0%

genome coverage using a combination of multiplex amplicon and Sanger sequencing.[29] Previous

iterations of this scheme included IIA resulting in lower amplification efficiency due to the degree of

genetic variation between the genotypes. Unlike primer schemes for amplicon-based sequencing,

hybrid capture allows for the enrichment of all six subgenotypes using a pan-HAV probe panel.

Moreover, hybrid capture can tolerate thousands of probes, meaning additional targets can be added to

the current panel to facilitate robust pathogen surveillance.

Patient samples

After observing potential target loss from column-based concentration in the optimisation experiment,

vacuum concentration was implemented with the clinical specimen as well as using a greater RNA

extract input volume (30μL) prior to enrichment. As a result, mean read depth and genome coverage

from patient samples increased compared to contrived samples with similar Cτ values. At a minimum

read depth of ten, complete genomes were recovered from AUSMDU00085964 and

AUSMDU00085965, and near complete from AUSMDU00085966 (93·3%). However, 99·9% of the

positions in AUSMDU00085966 were covered by one or more reads, suggesting the possibility of

recovering a complete genome with greater input volume or sequencing depth. Indeed, combining

reads from technical duplicates yields 97·7% coverage and 46·7 mean read depth. Regardless, such

recovery at this Cτ is remarkable given the difficulty of detecting subgenotype IIIA. Recently, a

reverse transcription-PCR (rRT-PCR) HAV subgenotyping assay found the LOD for IIIA to be 10

RNA copies per reaction, equivalent to 34·2 and 33·9 Cτ for singleplex and triplex reactions,

respectively.[54] Whereas a subgenotype-specific optimised reverse transcription quantitative real-time

PCR (RT-qPCR) assay found the limit of detection for IIIA to be 5000 copies per reaction, equivalent

to Cτ near 41·3.[55] This may explain why subgenotyping data was not available for

AUSMDU00085965, or typing had not been requested.

It has been demonstrated that the whole genome can provide greater geographic and temporal

resolution for virus phylogenetics, generally.[28] For HAV, specifically, WGS has been shown to

increase phylogenetic resolution and provide additional context in the absence of epidemiological

data.[27,29] Even though substitutions per site were slightly higher in the VP1/2A region compared to the

whole genome sequence (0·012 versus 0·011), phylogenetic analysis comparing whole genomes to

the top VP1/2A hits provided additional resolution due to the sequences in the alignment including

additional regions around the VP1/2A junction (Figure 3B-C). The previous difficulty of WGS HAV

is reflected in the sequence database where few complete genomes are available, thus resulting in high

similarity to sequences more than 15 years old (Figure 3A). Until HAV genomes are better

represented in these databases, it is recommended that subgenomic regions are used to select closely

related sequences for phylogenetic analysis of the whole genome.

In silico prediction

We observed high capture efficiency in two of the six subgenotypes *in vitro*. Similarly, *in silico*

prediction shows broad specificity across all human subgenotypes with one or more probes covered at

>92% genome positions (Figure 2). Analysis of low probe coverage found an average of 1·1 120-

kmer regions, representing less than 2% of the HAV genome. While low probe coverage regions were

identified *in silico*, variables such as random fragmentation and hybridisation temperature can

improve efficiency *in vitro*. In fact, we did not observe significantly lower read depth in regions of the

enriched contrived samples where low probe coverage was predicted in the control sequence.

Limitations

This study serves as a proof-of-concept for the feasibility of a highly sensitive culture-agnostic

method for HAV WGS, however, additional work is needed to further optimise and validate the

approach for implementation in public health. For example, more complex sample types of public

health relevance remain untested, such as stool, wastewater, or shellfish. Promising results have been

found from ultra-deep sequencing of wastewater enriched with a broad viral discovery probe panel,

yielding three partial HAV genomes (1482—6729nts).[56,57] Cost may also be a limiting factor for

wider implementation. In the present study, the price per sample was $157AUD, approximately three-

times the cost of highly multiplexed amplicon sequencing.[58] However, increased multiplexing as well

as additional optimisation to increase target read proportions could lower per-sample costs.

Furthermore, we anticipate the value of this approach to be the greatest for supporting food-borne

surveillance, where PCR-based amplification is limited by low, degraded viral input and the presence

of inhibitors.[59,60] Finally, overnight hybridisation was used to accommodate hands-on staffing

schedules. Implementation of liquid handing automation could bring the turnaround time from

extraction to sequencer to under 24 hours.

Conclusion

This study presents, for the first time, a solitary approach for achieving highly sensitive WGS of HAV from clinical and food samples, while proving relatively cost-effective. WGS of HAV can support outbreak investigations by offering enhanced phylogenetic resolution and simultaneously facilitate the refinement and optimisation of molecular diagnostic assays through the deposition of genome data in public databases. In conclusion, flexible oligo design and hybridisation-based enrichment make this a promising workflow for streamlining the surveillance of enteric viruses, thereby furthering the genomic capacities of public health laboratories.

Acknowledgements

This work was supported by the National Health and Medical Research Council, Australia Partnership Grant (GNT1149991) and the Australian Government Medical Research Future Fund, Genomics Health Futures Mission Flagships – Pathogen Genomics Grant (FSPGN000045). SEZ is supported by the Melbourne Research Scholarship from the University of Melbourne.

We are grateful to Dr Andrew Gador-Whyte and the Department of Microbiology at Austin Health for their assistance. We thank the Victorian Infectious Disease Reference Laboratory for their valuable guidance in the conceptualization of this project. We would also like to show our gratitude to Dr. Ketan Patel for insightful comments on the manuscript.

390 **Tables and Figures**

					Unenriched		Enriched	
Sample	**Matrix**	**Cτ**	**Copy no. (copies/μL)**	**Concentrated**	**Mean RD**	**Coverage**	**Mean RD**	**Coverage**
BerryLow	Berry	Undet.	Undet.	N	0.0	0.0	0.2	0.0
				Y†	0.0	0.0	0.2	0.0
BerryMid		40.2	0.45	N	0.0	0.0	2.6	1.1
				Y†	0.0	0.0	2.7	2.3
BerryHigh		35.1	11.2	N	0.0	0.0	12.0	60.5
				Y†	0.1	0.0	14.8	74.1
SerumLow	Serum	41.0	0.28	N	3.1	1.9	1.2	1.0
				Y†	2.5	0.9	12.5	10.3
SerumMid		36.6	4.4	N	2.1	0.0	19.2	77.7
				Y†	2.0	0.0	28.0	80.8
SerumHigh		33.6	27.9	N	1.2	0.0	324.7	100.0
				Y†	2.3	0.6	160.7	99.6
AUSMDU00085964-1	Serum	35.8	7.1	Y‡	-	-	2455.3	100.0
AUSMDU00085964-2				Y‡	*	*	*	*
AUSMDU00085966-1		42.7	0.09	Y‡	-	-	24.3	93.3
AUSMDU00085966-2				Y‡	-	-	23.0	89.5
AUSMDU00085965-1		34.7	14.07	Y‡	-	-	3446.4	100.0
AUSMDU00085965-2				Y‡	-	-	2387.9	100.0

Table 1. Summary of sample variables and genome coverage results. Undetermined (Undet.) Cτ values occur when the target is not present or is present

below the limit of detection of the assay used. Copy number is the genome copies/μL quantified from the RNA extract as determined by the ISO 15216-1

HAV quantification real-time RT-PCR protocol. Mean read depth (RD) is calculated as the average number of deduplicated reads covering one position in the

396   genome. Coverage reported here is the percentage of genome positions with a depth of 10 or more reads. A summary of positive- and negative controls can be

397   found in Supplemental Table 4.

398   [†]Zymo Clean and Concentrator -5 kit.

399   [‡]Vacuum concentration.

400   [*]No indices belonging to AUSMDU00085964-2 were identified in the sequenced reads, suggesting an error occurred during library preparation.

Figure 1. A) Mean-fold enrichment between paired pre- and post-enrichment samples. To avoid infinite values or overestimation using a small pseudocount,

a depth of 1 was assigned to positions in pre-enriched samples where the corresponding position in the post-enriched sample was greater than 0 under the

biological assumption that one or more reads must have been present for enrichment to have occurred. B) Genome coverage by spike-in titre levels at read

depth thresholds of >0, ≥5, and ≥10.

408 **Figure 2**. HAV read statistics of enriched clinical specimen. A) Taxonomic classification of sample reads averaged over technical duplicates belonging to

409 *Hepatovirus A*, non-HAV viral taxonomies, and unclassified. B) Box and whisker plot of genome coverage by sample Cτ at read depth thresholds of >0, ≥5,

410 and ≥10.

Figure 3. Maximum likelihood trees comparing WGS- and VP1/2A-query results. Ancestral nodes were traversed to clearly visualise patient samples (blue). Nodes with high bootstrap support (≥80%) are coloured in purple. Trees were visualised using toytree (v.2.0.5).[62] A) WGS consensus sequences in the context of WG-query sequences (best-fit model = TIM2+F+I+R3). B) VP1/2A consensus sequences in the context of VP1/2A-query sequences (best-fit model = TIM2+F+I+G4). C) WGS consensus sequences in the context of VP1/2A-query sequences (best-fit model = TIM2+F+I+G4).

Figure 4. *In silico* prediction of probe efficiency, averaged by subgenotype and stratified by probe

coverage depth. Percentage annotation indicates the mean[*] predicted percent genome coverage at

respective probe depths.

[*]Subgenotypes IIB and IIIB each have a single genome available for comparison (AB279735.1 and

AY644670.1, respectively).

Supplemental tables and figures

Additional data and supplemental materials are available from https://doi.org/10.26188/23648025.

S Table 1. Resultant pan-HAV oligos designed for capture of all six human subgenotypes of HAV.

S Table 2. GenBank accession numbers for sequences used to design pan-HAV oligos and associated subgenotype and collection metadata. Date of sample collection, where available, is formatted as DD-MM-YYYY.

S Table 3. GenBank accession numbers for sequences used for *in silico* prediction of the pan-HAV oligo design efficiency, including associated subgenotype and collection metadata. Date of sample collection, where available, is formatted as DD-MM-YYYY.

S Table 4. Summary of positive and negative controls from the optimisation experiment and resultant genome coverage results. Undetermined (Undet.) Cτ values occur when the target is not present or is present below the limit of detection of the assay used. Copy number is the genome copies/μL quantified from the RNA extract as determined by the ISO 15216-1 HAV quantification real-time RT-PCR protocol. Mean RD is calculated as the average number of deduplicated reads covering one position in the genome. Coverage reported here is the percentage of genome positions with a depth of 10 or more reads.

- Indicates no reads from the corresponding index were present in the sequence data.

S Figure 1. Read length distribution of spike-in sample libraries measured before quality control.

References

1.   Koff, R. S. Hepatitis A. *Lancet* **351**, 1643–1649 (1998).

2.   Shapiro, C. N. & Margolis, H. S. Worldwide epidemiology of hepatitis A virus infection. *J.*

Hepatol. **18 Suppl 2**, S11-4 (1993).

3.   Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive

immunization: recommendations of the Advisory Commitee on Immunization Practices (ACIP).

MMWR Recomm. Rep. (1999).

4.   Advisory Committee on Immunization Practices (ACIP), Fiore, A. E., Wasley, A. & Bell, B. P.

Prevention of hepatitis A through active or passive immunization: recommendations of the

Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm. Rep.* **55**, 1–23

(2006).

5.   Klevens, R. M., Denniston, M. M., Jiles-Chapman, R. B. & Murphy, T. V. Decreasing immunity

to hepatitis A virus infection among US adults: Findings from the National Health and Nutrition

Examination Survey (NHANES), 1999-2012. *Vaccine* **33**, 6192–6198 (2015).

6.   Bell, B. P. *et al.* The diverse patterns of hepatitis A epidemiology in the United States-

implications for vaccination strategies. *J. Infect. Dis.* **178**, 1579–1584 (1998).

7.   Staes, C. J. *et al.* Sources of infection among persons with acute hepatitis A and no identified risk

factors during a sustained community-wide outbreak. *Pediatrics* **106**, E54 (2000).

8.   Mutsch, M., Spicher, V. M., Gut, C. & Steffen, R. Hepatitis A virus infections in travelers, 1988-

2004. *Clin. Infect. Dis.* **42**, 490–497 (2006).

9.   Klevens, R. M. *et al.* The evolving epidemiology of hepatitis a in the United States: incidence

and molecular epidemiology from population-based surveillance, 2005-2007. *Arch. Intern. Med.*

170, 1811–1818 (2010).

10.   Beebeejaun, K. *et al.* Outbreak of hepatitis A associated with men who have sex with men

(MSM), England, July 2016 to January 2017. *Euro Surveill.* **22**, (2017).

11. Freidl, G. S. *et al.* Hepatitis A outbreak among men who have sex with men (MSM)

predominantly linked with the EuroPride, the Netherlands, July 2016 to February 2017. *Euro*

Surveill. **22**, (2017).

12. Latash, J. *et al.* Notes from the Field: Increase in Reported Hepatitis A Infections Among Men

Who Have Sex with Men - New York City, January-August 2017. *MMWR Morb. Mortal. Wkly.*

Rep. **66**, 999–1000 (2017).

13. Foster, M. *et al.* Hepatitis A Virus Outbreaks Associated with Drug Use and Homelessness -

California, Kentucky, Michigan, and Utah, 2017. *MMWR Morb. Mortal. Wkly. Rep.* **67**, 1208–

1210 (2018).

14. Friesema, I. H. *et al.* Spillover of a hepatitis A outbreak among men who have sex with men

(MSM) to the general population, the Netherlands, 2017. *Euro Surveill.* **23**, (2018).

15. Ndumbi, P. *et al.* Hepatitis A outbreak disproportionately affecting men who have sex with men

(MSM) in the European Union and European Economic Area, June 2016 to May 2017. *Euro*

Surveill. **23**, (2018).

16. Foster, M. A. *et al.* Increase in Hepatitis A Virus Infections - United States, 2013-2018. *MMWR*

Morb. Mortal. Wkly. Rep. **68**, 413–415 (2019).

17. Probert, W. S., Gonzalez, C., Espinosa, A. & Hacker, J. K. Molecular Genotyping of Hepatitis A

Virus, California, USA, 2017-2018. *Emerg. Infect. Dis.* **25**, 1594–1596 (2019).

18. Haddix, M. *et al.* Use of Molecular Epidemiology to Inform Response to a Hepatitis A Outbreak

- Los Angeles County, California, October 2018-April 2019. *MMWR Morb. Mortal. Wkly. Rep.*

69, 820–824 (2020).

19. Foster, M. A. *et al.* Widespread Hepatitis A Outbreaks Associated with Person-to-Person

Transmission - United States, 2016-2020. *MMWR Morb. Mortal. Wkly. Rep.* **71**, 1229–1234

(2022).

20. Batdorf, S. J. *et al.* Estimated Medicaid Costs Associated with Hepatitis A During an Outbreak -

West Virginia, 2018-2019. *MMWR Morb. Mortal. Wkly. Rep.* **70**, 269–272 (2021).

21.   Helmick, M. J., Morrow, C. B., White, J. H. & Bordwine, P. Widespread Community

Transmission of Hepatitis A Virus Following an Outbreak at a Local Restaurant - Virginia,

September 2021-September 2022. *MMWR Morb. Mortal. Wkly. Rep.* **72**, 362–365 (2023).

22.   Kroneman, A. *et al.* Usability of the international HAVNet hepatitis A virus database for

geographical annotation, backtracing and outbreak detection. *Euro Surveill.* **23**, (2018).

23.   Robertson, B. H. *et al.* Genetic relatedness of hepatitis A virus strains recovered from different

geographical regions. *J. Gen. Virol.* **73 (Pt 6)**, 1365–1377 (1992).

24.   Nainan, O. V. *et al.* Hepatitis a molecular epidemiology in the United States, 1996-1997: sources

of infection and implications of vaccination policy. *J. Infect. Dis.* **191**, 957–963 (2005).

25.   Costa-Mattioli, M. *et al.* Genetic variability of hepatitis A virus. *J. Gen. Virol.* **84**, 3191–3201

(2003).

26.   Costa-Mattioli, M. *et al.* Molecular evolution of hepatitis A virus: a new classification based on

the complete VP1 protein. *J. Virol.* **76**, 9516–9525 (2002).

27.   Vaughan, G. *et al.* Genetic relatedness among hepatitis A virus strains associated with food-

borne outbreaks. *PLoS One* **8**, e74546 (2013).

28.   Dudas, G. & Bedford, T. The ability of single genes vs full genomes to resolve time and space in

outbreak analysis. *BMC Evol. Biol.* **19**, 232 (2019).

29.   Cleary, N. G., Bryant, P. W., Lamson, D. M., Newman, A. P. & St George, K. A custom

hepatitis A virus assay for whole-genome sequencing. *J. Virol. Methods* **312**, 114649 (2023).

30.   Moratorio, G. *et al.* Bayesian coalescent inference of hepatitis A virus populations: evolutionary

rates and patterns. *J. Gen. Virol.* **88**, 3039–3042 (2007).

31.   Vaughan, G. *et al.* Hepatitis A virus: host interactions, molecular epidemiology and evolution.

Infect. Genet. Evol. **21**, 227–243 (2014).

32.   Lee, G.-Y. *et al.* Genotyping and Molecular Diagnosis of Hepatitis A Virus in Human Clinical

Samples Using Multiplex PCR-Based Next-Generation Sequencing. *Microorganisms* **10**, (2022).

33.   Bonsall, D. *et al.* ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-

genome sequencing of HCV and other highly diverse pathogens. *F1000Res.* **4**, 1062 (2015).

34. International Organization for Standardization. *Microbiology of the Food Chain–Horizontal*

Method for Determination of Hepatitis A Virus and Norovirus Using Real-time RT-PCR- Part1:

Method for Quantification. (2017).

35. International Organization for Standardization. *Microbiology of the Food Chain-Horizontal*

Method for Determination of Hepatitis A Virus and Norovirus Using Real-time RT-PCR- Part2:

Method for Detection. (2019).

36. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads.

EMBnet J. **17**, 10 (2011).

37. Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2. *Genome*

Biol. **20**, 257 (2019).

38. Li, H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* **34**, 3094–3100

(2018).

39. Li, H. New strategies to improve minimap2 alignment accuracy. *Bioinformatics* **37**, 4572–4574

(2021).

40. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, (2021).

41. Okonechnikov, K., Conesa, A. & García-Alcalde, F. Qualimap 2: advanced multi-sample quality

control for high-throughput sequencing data. *Bioinformatics* **32**, 292–294 (2016).

42. Ewels, P., Magnusson, M., Lundin, S. & Käller, M. MultiQC: summarize analysis results for

multiple tools and samples in a single report. *Bioinformatics* **32**, 3047–3048 (2016).

43. Prjibelski, A., Antipov, D., Meleshko, D., Lapidus, A. & Korobeynikov, A. Using SPAdes DE

Novo Assembler. *Curr. Protoc. Bioinformatics* **70**, e102 (2020).

44. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search

tool. *J. Mol. Biol.* **215**, 403–410 (1990).

45. HAVNet. *National Institute for Public Health and the Environment (RIVM)* www.havnet.nl.

46. Grubaugh, N. D. *et al.* An amplicon-based sequencing framework for accurately measuring

intrahost virus diversity using PrimalSeq and iVar. *Genome Biol.* **20**, 8 (2019).

47. Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7:

improvements in performance and usability. *Mol. Biol. Evol.* **30**, 772–780 (2013).

48.   Nguyen, L.-T., Schmidt, H. A., von Haeseler, A. & Minh, B. Q. IQ-TREE: a fast and effective

551   stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol. Biol. Evol.* **32**, 268–

552   274 (2015).

553   49.   Huddleston, J. *et al.* Augur: a bioinformatics toolkit for phylogenetic analyses of human

554   pathogens. *J. Open Source Softw.* **6**, 2906 (2021).

555   50.   Kuchinski, K. S., Duan, J., Himsworth, C., Hsiao, W. & Prystajecky, N. A. ProbeTools:

556   designing hybridization probes for targeted genomic sequencing of diverse and hypervariable

557   viral taxa. *BMC Genomics* **23**, 579 (2022).

558   51.   Virtanen, P. *et al.* SciPy 1.0: fundamental algorithms for scientific computing in Python. *Nat.*

559   *Methods* **17**, 261–272 (2020).

560   52.   Chen, H., Wang, W., Wang, S. & Hu, Y. Near-Complete Genome Sequence of a Hepatitis A

561   Subgenotype IB Virus Isolated from Frozen Raspberries. *Microbiol Resour Announc* **8**, (2019).

562   53.   Gnirke, A. *et al.* Solution hybrid selection with ultra-long oligonucleotides for massively parallel

563   targeted sequencing. *Nat. Biotechnol.* **27**, 182–189 (2009).

564   54.   Probert, W. S. & Hacker, J. K. New Subgenotyping and Consensus Real-Time Reverse

565   Transcription-PCR Assays for Hepatitis A Outbreak Surveillance. *J. Clin. Microbiol.* **57**, (2019).

566   55.   Coudray-Meunier, C. *et al.* Hepatitis A virus subgenotyping based on RT-qPCR assays. *BMC*

567   *Microbiol.* **14**, 296 (2014).

568   56.   Briese, T. *et al.* Virome Capture Sequencing Enables Sensitive Viral Diagnosis and

569   Comprehensive Virome Analysis. *MBio* **6**, e01491-15 (2015).

570   57.   Schaeffer, J., Desdouits, M., Besnard, A. & Le Guyader, F. S. Looking into sewage: how far can

571   metagenomics help to detect human enteric viruses? *Front. Microbiol.* **14**, 1161674 (2023).

572   58.   Gohl, D. M. *et al.* A rapid, cost-effective tailed amplicon method for sequencing SARS-CoV-2.

573   *BMC Genomics* **21**, 863 (2020).

574   59.   Lee, D.-Y., Cho, S.-R., Chae, S.-J., Choi, W. & Han, M.-G. Evaluation of a test method to detect

575   hepatitis A virus in salted shellfish. *J. Food Saf.* **41**, (2021).

576   60. Fitzpatrick, A. H. *et al.* Amplicon-Based High-Throughput Sequencing Method for Genotypic

577   Characterization of Norovirus in Oysters. *Appl. Environ. Microbiol.* e0216522 (2023)

578   doi:10.1128/aem.02165-22.

579   61. Eaton, D. A. R. Toytree: A minimalist tree visualization and manipulation library for Python.

580   *Methods Ecol. Evol.* **11**, 187–191 (2020).